Tandem Diabetes Care (TNDM) Cash from Operations Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.36% |
| Dec 31, 2025 | -8.47% |
| Sep 30, 2025 | -10.71% |
| Jun 30, 2025 | -21.18% |
| Mar 31, 2025 | 2.39% |
| Dec 31, 2024 | -11.23% |
| Sep 30, 2024 | 3.07% |
| Jun 30, 2024 | -28.31% |
| Mar 31, 2024 | -14.16% |
| Dec 31, 2023 | -20.21% |
| Sep 30, 2023 | 15.05% |
| Jun 30, 2023 | 1.22% |
| Mar 31, 2023 | -8.35% |
| Dec 31, 2022 | 20.11% |
| Sep 30, 2022 | 26.65% |
| Jun 30, 2022 | 19.83% |
| Mar 31, 2022 | 21.64% |
| Dec 31, 2021 | 28.07% |
| Sep 30, 2021 | 31.15% |
| Jun 30, 2021 | 32.87% |
| Mar 31, 2021 | 30.60% |
| Dec 31, 2020 | 28.38% |
| Sep 30, 2020 | 24.70% |
| Jun 30, 2020 | 23.10% |
| Mar 31, 2020 | -5.99% |
| Dec 31, 2019 | 28.00% |
| Sep 30, 2019 | 29.87% |
| Jun 30, 2019 | 17.15% |
| Mar 31, 2019 | 24.63% |
| Dec 31, 2018 | 25.41% |
| Sep 30, 2018 | 20.60% |
| Jun 30, 2018 | 15.01% |
| Mar 31, 2018 | -6.85% |